Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.

Name: Αlpha¹ Rigor Record — Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
Item: Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
Rating: 100
Author: Αlpha¹

Long GV, Nair N, Marbach D, Scolyer RA, Wilson S, Cotting D, Staedler N, Amaria RN, Ascierto PA, Tarhini AA, Robert C, Hamid O, Gaudy-Marqueste C, Lebbe C, Munoz-Couselo E, Menzies AM, Pages C, Curigliano G, Mandala M, Jessop N, Bader U, Perdicchio M, Teichgräber V, Muecke M, Markert C, Blank C

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.5★ (Adequate), 0 critical, 3 high issues for “Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted phase 1b/2 umbrella trial with clear scientific rationale, appropriate design, and transparent reporting. Minor reporting gaps include lack of explicit informed consent statement, no mention of a reporting guideline, and some p-values reported as thresholds.

Both reviewers classified the study as interventional and agreed on all dimensions. The synthesis adopted the more conservative checklist ratings where reviewers diverged (e.g., power analysis as not applicable, informed consent as reported but inadequate). The statistics verification covered only 3 tests; the rest are unverified.

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites key prior work (NADINA, SWOG-1801) and discusses their limitations, particularly the high toxicity of nivolumab plus ipilimumab. The rationale for the study is logically developed from the need for alternative strategies with improved safety and efficacy. The limitations of prior research are addressed by designing a study to evaluate novel combinations with a focus on safety and biomarkers.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes its scientific foundation by citing prior trials (NADINA, SWOG-1801) and explaining the rationale for testing tobemstomig and other combinations.

Evidence

paraphrase[Introduction, paragraph 1]

“In the phase 3 NADINA study, neoadjuvant nivolumab plus ipilimumab followed by surgery and response-driven adjuvant therapy resulted in a 68% reduction in the risk of disease recurrence or death versus surgery plus adjuvant nivolumab. However, a substantially higher rate of grade 3 or higher TRAEs was observed with neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab (29.7% versus 14.7%, respectively).”

direct quote[Introduction, paragraph 2]

“Therefore, there is a need for alternative strategies and novel combinations to increase MPR, reduce toxicities and enable personalized neoadjuvant treatment options.”